CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of head and neck cancers.
  
  LEARNING OBJECTIVES

  • Appraise clinical trial data documenting the efficacy and safety of immune checkpoint inhibitors for recurrent or metastatic squamous cell carcinoma of the head and neck, and optimally sequence approved agents for patients with newly diagnosed or progressive disease.
  • Appreciate published Phase III data with novel anti-PD-1 antibodies in combination with platinum-based chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma in preparation for the potential availability of this approach.
  • Evaluate the efficacy and safety of multitargeted tyrosine kinase inhibitors for advanced thyroid cancer, and discern how these agents can be optimally employed in first- and later-line patient care.
  • Recognize the spectrum and prevalence of potentially targetable genomic alterations in patients with head and neck and thyroid cancer, and discuss the means by which these alterations contribute to tumor growth and proliferation.
  • Analyze available safety and efficacy results with novel RET inhibitors for patients with RET-driven thyroid cancer, and appropriately integrate these agents into treatment algorithms.
  • Consider the clinical relevance of NTRK gene fusions in head and neck and thyroid cancer, and appreciate available research with and FDA endorsements for TRK inhibitors.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for head and neck and thyroid cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  Lecture Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Ezra Cohen, MD
  Chief, Division of Hematology/Oncology
  Department of Medicine
  Co-Director, San Diego Center for Precision Immunotherapy
  Co-Director, IEM Center for Engineering in Cancer
  Associate Director for Clinical Sciences
  Co-Leader, Solid Tumor Therapeutics Program
  Co-Director, Hanna and Mark Gleiberman Head and Neck Cancer Center
  UC San Diego Moores Cancer Center
  UC San Diego School of Medicine
  La Jolla, California
  
  Board of Directors: PsiOxus Therapeutics; Consulting Agreements: Axelia Oncology, CEL-SCI, Eisai Inc, Hookipa Pharma Inc, Istari Oncology, Janssen Biotech Inc, KAHR, Mana Therapeutics, Merck, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Nectin Therapeutics, Pangea Biomed, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: Ayala Pharmaceuticals, Kura Oncology; Scientific Advisory Board: Kinnate Biopharma; Stock Ownership: Kinnate Biopharma, Primmune Therapeutics.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals, Exelixis Inc, and Merck.
  
  Release date: August 2022
  Expiration date: August 2023